menu
    • menu
    [{"orgOrder":0,"company":"Kailera Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"KAI-9531","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kailera Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kailera Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"14","companyTruncated":"Kailera Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"Kailera Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"KAI-9531","moa":"","graph1":null,"graph2":null,"graph3":"Kailera Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Kailera Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":null,"companyTruncated":"Kailera Therapeutics \/ Atlas Venture"}]

    Find Clinical Drug Pipeline Developments & Deals by Kailera Therapeutics

    Menu

    Kailera Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kailera Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Kailera Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAI-9531

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Atlas Venture

                            Deal Size : $400.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kailera Launches with $400M to Develop Therapies for Obesity and Related Conditions

                            Details : The financing aims to lead the clinical development of the company's lead product HRS9531 (KAI-9531), GLP-1 receptor dual agonist formulated as an injectable peptide for the treatment of obesity.

                            Brand Name : HRS9531

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : KAI-9531

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Atlas Venture

                            Deal Size : $400.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kailera Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed

                            Kailera Therapeutics

                            U.S.A arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAI-9531

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Atlas Venture

                            Deal Size : $400.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kailera Launches with $400M to Advance China-Developed Obesity Assets

                            Details : The proceeds will fund the clinical development of the company's lead product HRS9531 (KAI-9531), GLP-1 receptor dual agonist formulated as an injectable peptide for the treatment of obesity.

                            Brand Name : HRS9531

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : KAI-9531

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Atlas Venture

                            Deal Size : $400.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth